We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Distinct Bile Acid Signature in Parkinson's Disease With Mild Cognitive Impairment.
- Authors
Kun Nie; Yanyi Li; Jiahui Zhang; Yuyuan Gao; Yihui Qiu; Rong Gan; Yuhu Zhang; Lijuan Wang
- Abstract
Backgrounds: Bile acid (BA) plays a crucial role in various neurodegenerative diseases, including Parkinson's disease (PD). However, no clinical evidence supports BA's potential role in patients with PD with mild cognitive impairment (PD-MCI). Objectives: This study aimed at investigating the differential BA profile between patients with PD-MCI and those with normal cognitive function (PD-NC). Methods: Ultra-high performance liquid chromatography-MS/MS was applied for BA quantitation. After between-group differences of the BA profile were addressed, orthogonal projections to latent structures--discriminant analysis (OPLS-DA) and the area under the receiver-operating-characteristic curve (AUC-ROC) were implemented for further verification. Results: Lower levels of chenodeoxycholic acid (CDCA), cholic acid (CA), and ursodeoxycholic acid (UDCA) were significantly associated with PD-MCI (p < 0.01 for both; VIP = 2.67, 1.66, and 1.26, respectively). AUC-ROC were 78.1, 74.2, and 74.5% for CDCA, CA, and UDCA, respectively. Conclusion: CA, CDCA, and UDCA might be distinct BA signatures for patients with PD-MCI.
- Subjects
PARKINSON'S disease; MILD cognitive impairment; BILE acids; CHOLIC acid; CHENODEOXYCHOLIC acid
- Publication
Frontiers in Neurology, 2022, Vol 13, p1
- ISSN
1664-2295
- Publication type
Article
- DOI
10.3389/fneur.2022.897867